Table II.
Univariate and multivariate Cox proportional analysis for survival.
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Parameter | Categories | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (years) | (≥60 vs. <60) | 1.616 (0.8484–3.081) | 0.136 | ||
| Sex | (male vs. female) | 1.165 (0.596–2.279) | 0.658 | ||
| Tumour location | (upper vs. other) | 1.342 (0.545–3.308) | 0.522 | ||
| Tumour size | (≥50 mm vs. <50 mm) | 1.517 (0.826–2.786) | 0.179 | ||
| Vascular invasion | (yes vs. no) | 1.998 (1.033–3.865) | 0.040 | 1.720 (0.882–3.352) | 0.111 |
| Lymphatic invasion | (yes vs. no) | 1.718 (0.876–3.370) | 0.115 | ||
| Nervous invasion | (yes vs. no) | 1.585 (0.795–3.158) | 0.190 | ||
| Tumour differentiation | (undifferentiated vs. differentiated) | 1.447 (0.789–2.652) | 0.232 | ||
| AJCC TNM stage | (III vs. I/II) | 3.398 (1.873–6.163) | <0.001 | 4.271 (2.289–7.969) | <0.001 |
| CEA level | (above normal vs. normal) | 1.272 (0.651–2.485) | 0.481 | ||
| CA 19-9 level | (above normal vs. normal) | 1.060 (0.470–2.388) | 0.889 | ||
| PP2A | (high vs. low) | 0.478 (0.234–0.973) | 0.042 | 0.317 (0.152–0.662) | 0.002 |
CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9; AJCC TNM, American Joint Committee on Cancer Tumour-Node-Metastasis; PP2A, serine/threonine-protein phosphatase 2A; HR, hazard ratio; CI, confidence interval.